---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021244"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:28:04.854757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Eliem Therapeutics Q1 net loss $22.3M; cash $109.4M funds operations into 2027

## Summary
- Net loss of $22.3M for Q1 2023 vs $13.2M in Q1 2022; includes $15.8M restructuring costs.
- Cash, cash equivalents and marketable securities $109.4M as of March 31, 2023.
- Presented initial preclinical data for lead Kv7 candidate ETX-123; IND-enabling studies initiated.
- Phase 1 clinical studies for ETX-123 planned to start in first half of 2024.
- R&D expenses $5.7M, G&A expenses $17.7M (includes $14.0M restructuring costs).

## SEC filing metadata
- accession: 0000950170-23-021244
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/0000950170-23-021244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/elym-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021244
- JSON: https://secwatch.observer/filing/0000950170-23-021244.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021244.txt

## Key facts
- Earnings Releases
  Climb Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $22.3 million.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss was $22.3 million
  - Result: reported results
  source text: Eliem Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/0000950170-23-021244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.